The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pediatric Drugs and Vaccines Market Research Report 2025
Synopsis
Children differ from adults in many aspects of pharmacotherapy, including capabilities for drug administration, medicine-related toxicity, and taste preferences. It is essential that pediatric medicines are formulated to best suit a child's age, size, physiologic condition, and treatment requirements. Therefore, the pediatric drug and vasccines specially serve for children.
The global Pediatric Drugs and Vaccines market was valued at US$ 95480 million in 2023 and is anticipated to reach US$ 176440 million by 2030, witnessing a CAGR of 9.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pediatric Drugs and Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pediatric Drugs and Vaccines.
Report Scope
The Pediatric Drugs and Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pediatric Drugs and Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pediatric Drugs and Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck & Co., Inc. (USA)
Abbott Laboratories (USA)
Amgen, Inc. (USA)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech, Inc. (USA)
GlaxoSmithKline plc. (UK)
Janssen Biologics B.V. (USA)
Actelion Pharmaceuticals
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (USA)
Allergan, Inc. (USA)
Novartis AG (Switzerland)
Novo Nordisk A/S (Denmark)
Pfizer, Inc. (USA)
Sanofi S.A (France)
Shionogi Inc. (USA)
Takeda
Segment by Type
Diphtheria
Influenza
Hepatitis
Pneumococcal Diseases
Meningococcal Diseases
Mumps
Others
Segment by Application
Newborn
Infant
Child
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pediatric Drugs and Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pediatric Drugs and Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Children differ from adults in many aspects of pharmacotherapy, including capabilities for drug administration, medicine-related toxicity, and taste preferences. It is essential that pediatric medicines are formulated to best suit a child's age, size, physiologic condition, and treatment requirements. Therefore, the pediatric drug and vasccines specially serve for children.
The global Pediatric Drugs and Vaccines market was valued at US$ 95480 million in 2023 and is anticipated to reach US$ 176440 million by 2030, witnessing a CAGR of 9.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pediatric Drugs and Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pediatric Drugs and Vaccines.
Report Scope
The Pediatric Drugs and Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pediatric Drugs and Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pediatric Drugs and Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck & Co., Inc. (USA)
Abbott Laboratories (USA)
Amgen, Inc. (USA)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech, Inc. (USA)
GlaxoSmithKline plc. (UK)
Janssen Biologics B.V. (USA)
Actelion Pharmaceuticals
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (USA)
Allergan, Inc. (USA)
Novartis AG (Switzerland)
Novo Nordisk A/S (Denmark)
Pfizer, Inc. (USA)
Sanofi S.A (France)
Shionogi Inc. (USA)
Takeda
Segment by Type
Diphtheria
Influenza
Hepatitis
Pneumococcal Diseases
Meningococcal Diseases
Mumps
Others
Segment by Application
Newborn
Infant
Child
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pediatric Drugs and Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pediatric Drugs and Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Pediatric Drugs and Vaccines Market Overview
1.1 Product Overview and Scope of Pediatric Drugs and Vaccines
1.2 Pediatric Drugs and Vaccines Segment by Type
1.2.1 Global Pediatric Drugs and Vaccines Market Value Comparison by Type (2024-2030)
1.2.2 Diphtheria
1.2.3 Influenza
1.2.4 Hepatitis
1.2.5 Pneumococcal Diseases
1.2.6 Meningococcal Diseases
1.2.7 Mumps
1.2.8 Others
1.3 Pediatric Drugs and Vaccines Segment by Application
1.3.1 Global Pediatric Drugs and Vaccines Market Value by Application: (2024-2030)
1.3.2 Newborn
1.3.3 Infant
1.3.4 Child
1.4 Global Pediatric Drugs and Vaccines Market Size Estimates and Forecasts
1.4.1 Global Pediatric Drugs and Vaccines Revenue 2019-2030
1.4.2 Global Pediatric Drugs and Vaccines Sales 2019-2030
1.4.3 Global Pediatric Drugs and Vaccines Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pediatric Drugs and Vaccines Market Competition by Manufacturers
2.1 Global Pediatric Drugs and Vaccines Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pediatric Drugs and Vaccines Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pediatric Drugs and Vaccines Average Price by Manufacturers (2019-2024)
2.4 Global Pediatric Drugs and Vaccines Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pediatric Drugs and Vaccines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pediatric Drugs and Vaccines, Product Type & Application
2.7 Pediatric Drugs and Vaccines Market Competitive Situation and Trends
2.7.1 Pediatric Drugs and Vaccines Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pediatric Drugs and Vaccines Players Market Share by Revenue
2.7.3 Global Pediatric Drugs and Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pediatric Drugs and Vaccines Retrospective Market Scenario by Region
3.1 Global Pediatric Drugs and Vaccines Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pediatric Drugs and Vaccines Global Pediatric Drugs and Vaccines Sales by Region: 2019-2030
3.2.1 Global Pediatric Drugs and Vaccines Sales by Region: 2019-2024
3.2.2 Global Pediatric Drugs and Vaccines Sales by Region: 2025-2030
3.3 Global Pediatric Drugs and Vaccines Global Pediatric Drugs and Vaccines Revenue by Region: 2019-2030
3.3.1 Global Pediatric Drugs and Vaccines Revenue by Region: 2019-2024
3.3.2 Global Pediatric Drugs and Vaccines Revenue by Region: 2025-2030
3.4 North America Pediatric Drugs and Vaccines Market Facts & Figures by Country
3.4.1 North America Pediatric Drugs and Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pediatric Drugs and Vaccines Sales by Country (2019-2030)
3.4.3 North America Pediatric Drugs and Vaccines Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pediatric Drugs and Vaccines Market Facts & Figures by Country
3.5.1 Europe Pediatric Drugs and Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pediatric Drugs and Vaccines Sales by Country (2019-2030)
3.5.3 Europe Pediatric Drugs and Vaccines Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pediatric Drugs and Vaccines Market Facts & Figures by Country
3.6.1 Asia Pacific Pediatric Drugs and Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pediatric Drugs and Vaccines Sales by Country (2019-2030)
3.6.3 Asia Pacific Pediatric Drugs and Vaccines Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Pediatric Drugs and Vaccines Market Facts & Figures by Country
3.7.1 Latin America Pediatric Drugs and Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pediatric Drugs and Vaccines Sales by Country (2019-2030)
3.7.3 Latin America Pediatric Drugs and Vaccines Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pediatric Drugs and Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa Pediatric Drugs and Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pediatric Drugs and Vaccines Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pediatric Drugs and Vaccines Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Pediatric Drugs and Vaccines Sales by Type (2019-2030)
4.1.1 Global Pediatric Drugs and Vaccines Sales by Type (2019-2024)
4.1.2 Global Pediatric Drugs and Vaccines Sales by Type (2025-2030)
4.1.3 Global Pediatric Drugs and Vaccines Sales Market Share by Type (2019-2030)
4.2 Global Pediatric Drugs and Vaccines Revenue by Type (2019-2030)
4.2.1 Global Pediatric Drugs and Vaccines Revenue by Type (2019-2024)
4.2.2 Global Pediatric Drugs and Vaccines Revenue by Type (2025-2030)
4.2.3 Global Pediatric Drugs and Vaccines Revenue Market Share by Type (2019-2030)
4.3 Global Pediatric Drugs and Vaccines Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pediatric Drugs and Vaccines Sales by Application (2019-2030)
5.1.1 Global Pediatric Drugs and Vaccines Sales by Application (2019-2024)
5.1.2 Global Pediatric Drugs and Vaccines Sales by Application (2025-2030)
5.1.3 Global Pediatric Drugs and Vaccines Sales Market Share by Application (2019-2030)
5.2 Global Pediatric Drugs and Vaccines Revenue by Application (2019-2030)
5.2.1 Global Pediatric Drugs and Vaccines Revenue by Application (2019-2024)
5.2.2 Global Pediatric Drugs and Vaccines Revenue by Application (2025-2030)
5.2.3 Global Pediatric Drugs and Vaccines Revenue Market Share by Application (2019-2030)
5.3 Global Pediatric Drugs and Vaccines Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck & Co., Inc. (USA)
6.1.1 Merck & Co., Inc. (USA) Corporation Information
6.1.2 Merck & Co., Inc. (USA) Description and Business Overview
6.1.3 Merck & Co., Inc. (USA) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck & Co., Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio
6.1.5 Merck & Co., Inc. (USA) Recent Developments/Updates
6.2 Abbott Laboratories (USA)
6.2.1 Abbott Laboratories (USA) Corporation Information
6.2.2 Abbott Laboratories (USA) Description and Business Overview
6.2.3 Abbott Laboratories (USA) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Abbott Laboratories (USA) Pediatric Drugs and Vaccines Product Portfolio
6.2.5 Abbott Laboratories (USA) Recent Developments/Updates
6.3 Amgen, Inc. (USA)
6.3.1 Amgen, Inc. (USA) Corporation Information
6.3.2 Amgen, Inc. (USA) Description and Business Overview
6.3.3 Amgen, Inc. (USA) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Amgen, Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio
6.3.5 Amgen, Inc. (USA) Recent Developments/Updates
6.4 Eli Lilly and Company (USA)
6.4.1 Eli Lilly and Company (USA) Corporation Information
6.4.2 Eli Lilly and Company (USA) Description and Business Overview
6.4.3 Eli Lilly and Company (USA) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Eli Lilly and Company (USA) Pediatric Drugs and Vaccines Product Portfolio
6.4.5 Eli Lilly and Company (USA) Recent Developments/Updates
6.5 F. Hoffmann-La Roche Ltd (Switzerland)
6.5.1 F. Hoffmann-La Roche Ltd (Switzerland) Corporation Information
6.5.2 F. Hoffmann-La Roche Ltd (Switzerland) Description and Business Overview
6.5.3 F. Hoffmann-La Roche Ltd (Switzerland) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.5.4 F. Hoffmann-La Roche Ltd (Switzerland) Pediatric Drugs and Vaccines Product Portfolio
6.5.5 F. Hoffmann-La Roche Ltd (Switzerland) Recent Developments/Updates
6.6 Genentech, Inc. (USA)
6.6.1 Genentech, Inc. (USA) Corporation Information
6.6.2 Genentech, Inc. (USA) Description and Business Overview
6.6.3 Genentech, Inc. (USA) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Genentech, Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio
6.6.5 Genentech, Inc. (USA) Recent Developments/Updates
6.7 GlaxoSmithKline plc. (UK)
6.6.1 GlaxoSmithKline plc. (UK) Corporation Information
6.6.2 GlaxoSmithKline plc. (UK) Description and Business Overview
6.6.3 GlaxoSmithKline plc. (UK) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GlaxoSmithKline plc. (UK) Pediatric Drugs and Vaccines Product Portfolio
6.7.5 GlaxoSmithKline plc. (UK) Recent Developments/Updates
6.8 Janssen Biologics B.V. (USA)
6.8.1 Janssen Biologics B.V. (USA) Corporation Information
6.8.2 Janssen Biologics B.V. (USA) Description and Business Overview
6.8.3 Janssen Biologics B.V. (USA) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Janssen Biologics B.V. (USA) Pediatric Drugs and Vaccines Product Portfolio
6.8.5 Janssen Biologics B.V. (USA) Recent Developments/Updates
6.9 Actelion Pharmaceuticals
6.9.1 Actelion Pharmaceuticals Corporation Information
6.9.2 Actelion Pharmaceuticals Description and Business Overview
6.9.3 Actelion Pharmaceuticals Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Actelion Pharmaceuticals Pediatric Drugs and Vaccines Product Portfolio
6.9.5 Actelion Pharmaceuticals Recent Developments/Updates
6.10 AstraZeneca Plc. (UK)
6.10.1 AstraZeneca Plc. (UK) Corporation Information
6.10.2 AstraZeneca Plc. (UK) Description and Business Overview
6.10.3 AstraZeneca Plc. (UK) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.10.4 AstraZeneca Plc. (UK) Pediatric Drugs and Vaccines Product Portfolio
6.10.5 AstraZeneca Plc. (UK) Recent Developments/Updates
6.11 Boehringer Ingelheim GmbH (Germany)
6.11.1 Boehringer Ingelheim GmbH (Germany) Corporation Information
6.11.2 Boehringer Ingelheim GmbH (Germany) Pediatric Drugs and Vaccines Description and Business Overview
6.11.3 Boehringer Ingelheim GmbH (Germany) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Boehringer Ingelheim GmbH (Germany) Pediatric Drugs and Vaccines Product Portfolio
6.11.5 Boehringer Ingelheim GmbH (Germany) Recent Developments/Updates
6.12 Bristol-Myers Squibb Company (USA)
6.12.1 Bristol-Myers Squibb Company (USA) Corporation Information
6.12.2 Bristol-Myers Squibb Company (USA) Pediatric Drugs and Vaccines Description and Business Overview
6.12.3 Bristol-Myers Squibb Company (USA) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Bristol-Myers Squibb Company (USA) Pediatric Drugs and Vaccines Product Portfolio
6.12.5 Bristol-Myers Squibb Company (USA) Recent Developments/Updates
6.13 Allergan, Inc. (USA)
6.13.1 Allergan, Inc. (USA) Corporation Information
6.13.2 Allergan, Inc. (USA) Pediatric Drugs and Vaccines Description and Business Overview
6.13.3 Allergan, Inc. (USA) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Allergan, Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio
6.13.5 Allergan, Inc. (USA) Recent Developments/Updates
6.14 Novartis AG (Switzerland)
6.14.1 Novartis AG (Switzerland) Corporation Information
6.14.2 Novartis AG (Switzerland) Pediatric Drugs and Vaccines Description and Business Overview
6.14.3 Novartis AG (Switzerland) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Novartis AG (Switzerland) Pediatric Drugs and Vaccines Product Portfolio
6.14.5 Novartis AG (Switzerland) Recent Developments/Updates
6.15 Novo Nordisk A/S (Denmark)
6.15.1 Novo Nordisk A/S (Denmark) Corporation Information
6.15.2 Novo Nordisk A/S (Denmark) Pediatric Drugs and Vaccines Description and Business Overview
6.15.3 Novo Nordisk A/S (Denmark) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Novo Nordisk A/S (Denmark) Pediatric Drugs and Vaccines Product Portfolio
6.15.5 Novo Nordisk A/S (Denmark) Recent Developments/Updates
6.16 Pfizer, Inc. (USA)
6.16.1 Pfizer, Inc. (USA) Corporation Information
6.16.2 Pfizer, Inc. (USA) Pediatric Drugs and Vaccines Description and Business Overview
6.16.3 Pfizer, Inc. (USA) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Pfizer, Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio
6.16.5 Pfizer, Inc. (USA) Recent Developments/Updates
6.17 Sanofi S.A (France)
6.17.1 Sanofi S.A (France) Corporation Information
6.17.2 Sanofi S.A (France) Pediatric Drugs and Vaccines Description and Business Overview
6.17.3 Sanofi S.A (France) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Sanofi S.A (France) Pediatric Drugs and Vaccines Product Portfolio
6.17.5 Sanofi S.A (France) Recent Developments/Updates
6.18 Shionogi Inc. (USA)
6.18.1 Shionogi Inc. (USA) Corporation Information
6.18.2 Shionogi Inc. (USA) Pediatric Drugs and Vaccines Description and Business Overview
6.18.3 Shionogi Inc. (USA) Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Shionogi Inc. (USA) Pediatric Drugs and Vaccines Product Portfolio
6.18.5 Shionogi Inc. (USA) Recent Developments/Updates
6.19 Takeda
6.19.1 Takeda Corporation Information
6.19.2 Takeda Pediatric Drugs and Vaccines Description and Business Overview
6.19.3 Takeda Pediatric Drugs and Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Takeda Pediatric Drugs and Vaccines Product Portfolio
6.19.5 Takeda Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pediatric Drugs and Vaccines Industry Chain Analysis
7.2 Pediatric Drugs and Vaccines Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pediatric Drugs and Vaccines Production Mode & Process
7.4 Pediatric Drugs and Vaccines Sales and Marketing
7.4.1 Pediatric Drugs and Vaccines Sales Channels
7.4.2 Pediatric Drugs and Vaccines Distributors
7.5 Pediatric Drugs and Vaccines Customers
8 Pediatric Drugs and Vaccines Market Dynamics
8.1 Pediatric Drugs and Vaccines Industry Trends
8.2 Pediatric Drugs and Vaccines Market Drivers
8.3 Pediatric Drugs and Vaccines Market Challenges
8.4 Pediatric Drugs and Vaccines Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
